Fluor's Q2 Beat Is A False Narrative — The Cash Flow Tells The Real Story

Fluor reported an adjusted EPS beat today — $0.91 versus the $0.71 estimate — and revenue came in at $4.33 billion, well above the $3.96 billion consensus. The stock still fell 3.3% on the day, and for good reason: the earnings headline is masking a company that remains deeply negative on free cash flow, cut its full-year guidance, and saw every insider sell shares over the past six months.

I've been very surprised that analysts have accepted Fluor's adjusted EPS beat as evidence of a turnaround. Adjusted metrics are designed to exclude what they exclude. In Fluor's case, they exclude a mountain of non-recurring items that happen to make the quarterly narrative look better than the underlying business. The GAAP net earnings for Q2 were $114 million, down approximately 95% from $2.46 billion a year ago — a comparison skewed by one-time equity-method earnings last year, but still a reminder that the adjusted number tells only part of the story.

More importantly, Fluor's trailing-twelve-month free cash flow is negative $41 million. That is not a company generating cash. That is a company consuming it. Operating cash flow over the same period came to $9 million, and capital expenditures totaled $50 million. Gross margin is negative 1.6%. Operating margin is negative 2.7%. ROIC is negative 7.3%. These are not the financials of an engineering firm executing a clean turnaround. They are the financials of a company still bleeding from the legacy fixed-price project wounds it spent the last two years trying to close out.

Let me explain the strategic pivot, because it is structurally sound even if the execution has yet to prove it. Fluor has deliberately moved away from risky fixed-price EPC contracts — where the company bears the full risk of cost overruns, scope creep, and supply chain delays — toward reimbursable work, where costs are passed through to the client and profit comes from managed fee structures. The shift is rational. At Q2 end, 85% of Fluor's $26.9 billion backlog was reimbursable, up from 80% a year ago. New awards in Q2 were 89% reimbursable, with $6.1 billion in total new bookings versus $1.8 billion in Q2 2025.

The government and nuclear work is real, not a narrative play. Mission Solutions — Fluor's government-facing segment — won $2.2 billion in new awards, including an EPC contract for Centrus's nuclear fuel enrichment facility. Backlog in that segment nearly doubled year-over-year to $4.0 billion. Fluor operates and manages U.S. nuclear weapons facilities, including the Naval Nuclear Laboratory and the Savannah River Site. Those are sticky, long-duration contracts in a sector where execution trust is harder to replace than in commercial construction. The Department of Energy and Department of Defense are not the most exciting end markets, but they are the most predictable.

That being the case, the problems are structural, not seasonal. Total backlog declined 5% year-over-year to $26.9 billion despite the surge in new awards, because the company continues to execute and close out the old pipeline faster than new work replaces it. More critically, management cut full-year 2026 adjusted EBITDA guidance — a rough cash-earnings proxy — from a range of $525–$560 million down to $500–$525 million, a midpoint reduction of roughly $30 million. The stated reason is the removal of second-half contribution from a divested Mexico joint venture, but the cut still signals that the full-year trajectory is not as robust as the Q2 headline suggests.

The cash flow situation is the strongest argument against buying this stock today. Fluor's quarterly operating cash flow was negative $317 million in Q2, though management attributes the bulk of that to a one-time $357 million tax payment related to the NuScale share monetization completed in April. Stripping that tax payment out, operating cash flow for the quarter was roughly even. Year-to-date, the operating cash outflow improved to $207 million from $307 million in H1 2025, so the trajectory is moving in the right direction. But "improving from very bad" is not the same as "generating cash," and it certainly isn't the same as producing the kind of free cash flow that supports dividend safety or aggressive share repurchases.

And yet Fluor is buying back its own stock at a $1.4 billion annual pace. The company repurchased $816 million in the first half of 2026, including $300 million in Q2 alone. It also received $1.83 billion from the NuScale share sales. So the balance sheet still looks healthy: $3.0 billion in cash and marketable securities, net debt of negative $2.17 billion, and a current ratio of 178%. But burning cash on buybacks when operating cash flow is barely positive is a capital allocation call that prioritizes the stock price over financial resilience. I have always favored dividend growth over buybacks, because dividends represent a tangible commitment to shareholders while buybacks can mask dilution or be timed poorly. Fluor's dividend yield is a meager 0.82% with no consecutive growth history. The buybacks are doing all the shareholder return lifting, and they're being funded by asset monetization, not operating cash flow.

Compare Fluor to KBR, its closest peer in the engineering-consulting-government-contracting space. KBR trades at 11.2x trailing earnings versus Fluor's 19.5x, carries a 1.77% dividend yield versus Fluor's 0.82%, and trades at 10.3x EV/EBITDA versus Fluor's implied multiple from an EV of $4.6 billion on roughly $510 million of guided EBITDA — a multiple of about 9x on the low end of guidance, which narrows the gap but doesn't close it. KBR also has a history of consecutive dividends. AECOM, a larger infrastructure and engineering peer, trades at a similar 19.0x trailing earnings but carries a 1.6% dividend yield and a 9.6x EV/EBITDA. Fluor's valuation advantage relative to AECOM and Jacobs (which trades at 49.8x trailing earnings) is real, but KBR offers both a cheaper multiple and a more meaningful yield.

The insider selling is the data point most investors will overlook. Twelve insider trades over the past six months, all sales. The CFO sold $1.5 million worth of shares. Multiple group presidents sold positions totaling well over $2 million combined. This is not unusual for compensation-related sales, but the unanimity — zero insider purchases in a six-month window while the company claims the turnaround is underway — is worth noting. Management is not betting against Fluor, but they're certainly not betting on it at $48.75.

The strongest counterargument to my view is straightforward: Fluor's reimbursable pivot is structural, not tactical, and the government/nuclear backlog is genuinely sticky revenue that will convert over the next several years at predictable margins. Mission Solutions backlog nearly doubled, new awards were up 245%, and the company is positioned to benefit from the defense-buildout cycle combined with the nuclear renaissance in the U.S. If you believe that trajectory holds, the current negative free cash flow is a transition cost, not a terminal condition.

I believe that trajectory is real, but I also believe the market has front-run it. The stock is up 23% year-to-date and up 15% on a rolling annual basis despite negative free cash flow, negative margins, and cut guidance. The forward P/E of roughly 15x on estimated 2027 earnings is not cheap. The price-to-sales ratio of 0.45x tells you the market still has a discount relative to revenue, but it also tells you Fluor is still a low-margin industrial operator, not a growth company in transition.

In my opinion, Fluor is a Hold at current levels. The reimbursable pivot and government/nuclear exposure are the real structural shifts, and they will likely improve cash flow over the next two to three years. But buying a company on negative free cash flow because its backlog is 85% reimbursable is a faith play, not an evidence play. The cut to guidance, the insider selling, the negative operating margins, and the buyback-funded capital allocation program all suggest the company is in the messy middle of a turnaround rather than on the other side of one.

For investors who want exposure to government engineering and nuclear infrastructure, KBR offers a cheaper multiple, a higher yield, and a proven dividend history. For investors who want the Fluor turnaround thesis, the entry point will come when free cash flow turns positive and guidance expands, not when adjusted EPS beats on project closeouts that are not repeatable. Until then, I rate Fluor as a Hold.